Kalaris Therapeutics, Inc. (Nasdaq: KLRS) announced its financial results for the year ended December 31, 2025, highlighting a significant increase in cash reserves and positive developments in its clinical programs. The company reported cash, cash equivalents, and marketable securities totaling $118 million, a substantial rise from $1.6 million in the previous year. This increase is attributed to the successful completion of a merger with AlloVir and an oversubscribed private placement that raised $50 million in December 2025.

The CEO, Andrew Oxtoby, emphasized the transformative year for Kalaris, noting the advancement of their clinical program for TH103, a treatment for neovascular age-related macular degeneration (nAMD). The company reported positive initial data from a Phase 1a single ascending dose study, which demonstrated clinical activity in visual acuity and retinal anatomy. The results showed a mean improvement in best corrected visual acuity and a significant reduction in central subfield thickness, indicating the potential effectiveness of TH103.

Looking ahead, Kalaris plans to initiate Phase 3 clinical trials by the end of 2027, with preliminary data from an ongoing Phase 1b/2 study expected in the first half of 2027. The company’s strategic focus on advancing its clinical pipeline, coupled with a strong financial position, positions it well for future growth and operational success. The net loss for 2025 was reported at $43.4 million, a decrease from $69.2 million in 2024, reflecting improved operational efficiency and cost management.

Overall, Kalaris Therapeutics is poised for a promising future as it continues to develop innovative treatments for retinal diseases, backed by solid financial results and a clear strategic direction.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.